Palo Alto (PANW) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Palo Alto Networks' SASE ARR surges 36% as Prisma Access Browser drives seat growth and builds a strong nine-figure sales pipeline.
Palo Alto Networks' Cortex XSIAM sees 200% ARR growth and $1B in bookings as it redefines SIEM with cloud-native, AI-powered tools.
Palo Alto (PANW) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
CYBR gains ground on PANW with standout earnings, AI-powered tools and expanding market reach.
Palo Alto Networks, Inc. (NASDAQ:PANW ) Bank of America Global Technology Conference June 3, 2025 11:40 AM ET Company Participants Nikesh Arora - Chairman & CEO Unidentified Analyst Good morning. What a great way to start our conference with Nikesh.
Palo Alto (PANW) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Here are three stocks favored by the Street's top pros, according to TipRanks.
Despite Q3 earnings beat, Palo Alto Networks stock dips on margin pressure and contract shifts. However, promising long-term prospects make the stock worth holding.
I'm doubling down on my buy rating for Palo Alto Networks, Inc. after the post-earnings pullback, and I see this as an attractive long-term entry point. Platform adoption, especially in software and AI-driven security, is accelerating, making me more confident in my long-term thesis. Despite minor misses in subscription growth, overall results beat expectations, and management raised EPS guidance, reinforcing my confidence in FY26 outperformance.
Palo Alto Networks' NASDAQ: PANW stock price plunged following the Q3 release and guidance update because the results and update were as expected. News, as expected, is not a catalyst for higher share prices but can sustain an uptrend if positive.
Palo Alto Networks' Q3 results were solid but not compelling enough to change my neutral stance; the stock could go either way from here. Revenue growth is stabilizing around 15% annually, which doesn't justify a premium valuation or excite me as an investor seeking higher inflection. Valuation at 30x next year's free cash flow is reasonable, but growth uncertainty keeps me on the sidelines despite strong free cash flow margins.